SORT1 and glioblastoma: The most optimal fusion construct resulted in a dramatic increase (>380-fold) in binding affinity to sortilin and was shown to increase extracellular PGRN levels in vitro in sortilin-expressing, PGRN-secreting human glioblastoma U-251 cells, with an EC50 comparable to that of latozinemab, suggesting a therapeutic potential.